Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 30;8(1):6752.
doi: 10.1038/s41598-018-25237-7.

Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease

Affiliations

Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease

Ekaterina Biterova et al. Sci Rep. .

Abstract

Coronary artery disease is the most common cause of death globally and is linked to a number of risk factors including serum low density lipoprotein, high density lipoprotein, triglycerides and lipoprotein(a). Recently two proteins, angiopoietin-like protein 3 and 4, have emerged from genetic studies as being factors that significantly modulate plasma triglyceride levels and coronary artery disease. The exact function and mechanism of action of both proteins remains to be elucidated, however, mutations in these proteins results in up to 34% reduction in coronary artery disease and inhibition of function results in reduced plasma triglyceride levels. Here we report the crystal structures of the fibrinogen-like domains of both proteins. These structures offer new insights into the reported loss of function mutations, the mechanisms of action of the proteins and open up the possibility for the rational design of low molecular weight inhibitors for intervention in coronary artery disease.

PubMed Disclaimer

Conflict of interest statement

A patent for the production system used to make the protein for structural studies using sulfhydryl oxidases in the cytoplasm of E.coli is held by the University of Oulu: Method for producing natively folded proteins in a prokaryotic host (Patent number 9238817; date of patent January 19th 2016). Inventor: Lloyd Ruddock

Figures

Figure 1
Figure 1
Crystal structure of the fibrinogen-like domains of Angptl3 and Angptl4. (A) Schematic of Angiopoietin-like protein domain architecture. Each angiopoietin and angiopoietin-like protein (except Angptl8) contains an N-terminal region predicted to be intrinsically disordered, a coiled-coil region and a C-terminal fibrinogen-like domain. (B) Structure of Angptl3 (left) and Angptl4 (right) fibrinogen-like domains. Each can be split into three subdomains A, B and P. Each structure is colored according to secondary structure elements with α-helices in gold (Angptl3) and violet (Angptl4), β-strands in cyan (Angptl4) and green (Angptl4) and loops in grey. Missing sections in the loops are indicated by dashed lines. Secondary structure elements are labeled and the N- and C-termini are indicated. (C) Electrostatic surface potential of Angptl3, the orientation is equivalent to that in panel B and rotated 90° around horizontal axis to see the underside of the P subdomain. Negative charge is shown in red and positive in blue. (D) As panel C but Angptl4.
Figure 2
Figure 2
Comparison of the Angptl3 and Angptl4 fibrinogen-like domains with angiopoietins. (A) Overlay of the Cα-trace of Angptl3 (blue, left) and Angptl4 (green, right) with those of Ang1 (yellow) and Ang2 (violet). (B) Comparison with Ca2+ binding site of Ang1 (light yellow) and Ang2 (light violet) of the equivalent region in Angptl3 (blue, top) and Angptl4 (green, bottom). Residues involved in Ca2+ binding are shown in stick representation and colored similarly to the protein they belong. Ca2+ ions are shown in ball representation. (C) Alignment of the proteins shown in panel A. Cysteines are highlighted in yellow and conserved amino acids in blue. The P subdomain is boxed and the Asp involved in calcium binding in Ang1 and Ang2 are indicated with arrowheads.
Figure 3
Figure 3
Structural analysis of mutations in Angptl3 which cause loss of function. (A) Angptl3 fibrinogen-like domain crystal structure with the sites of loss of function mutations depicted in ball and stick representation and highlighted in red. (B) Close up views of the environment of the mutated amino acids in panel A. Mutated residues are shown in ball and stick representation and neighboring or interacting residues are in stick representation. Residues are colored according to their location in the secondary structure elements with nitrogen atoms in blue, oxygen in red and sulfur in yellow. Potential hydrogen bonds are depicted as solid black lines.
Figure 4
Figure 4
Structural analysis of mutations in Angptl4 which cause loss of function. (A) Angptl4 fibrinogen-like domain crystal structure with the sites of mutations resulting in lower triglyceride levels are indicated in red, mutations leading to the increase of triglyceride levels are shown in blue. (B) Close up views of the environment of the mutated amino acids in panel A. Residues are depicted and colored as in Fig. 3.
Figure 5
Figure 5
Analysis of loss of function mutations (A) Coomassie stained SDS-PAGE gel of IMAC purified proteins. Upper gel Angptl3, lower gel Angptl4 (Supplementary Fig. 1 shows the full gels) (B) Thermal stability of purified wild-type Angptl3 determined by thermofluor. The insert panel shows the derivative of the change in fluorescence signal. Angptl3 shows cooperative unfolding.

Similar articles

  • Comparison of angiopoietin-like protein 3 and 4 reveals structural and mechanistic similarities.
    Gunn KH, Gutgsell AR, Xu Y, Johnson CV, Liu J, Neher SB. Gunn KH, et al. J Biol Chem. 2021 Jan-Jun;296:100312. doi: 10.1016/j.jbc.2021.100312. Epub 2021 Jan 20. J Biol Chem. 2021. PMID: 33482195 Free PMC article.
  • Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis.
    Wang Q, Oliver-Williams C, Raitakari OT, Viikari J, Lehtimäki T, Kähönen M, Järvelin MR, Salomaa V, Perola M, Danesh J, Kettunen J, Butterworth AS, Holmes MV, Ala-Korpela M. Wang Q, et al. Eur Heart J. 2021 Mar 21;42(12):1160-1169. doi: 10.1093/eurheartj/ehaa972. Eur Heart J. 2021. PMID: 33351885 Free PMC article.
  • Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.
    Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators; Stitziel NO, Stirrups KE, Masca NG, Erdmann J, Ferrario PG, König IR, Weeke PE, Webb TR, Auer PL, Schick UM, Lu Y, Zhang H, Dube MP, Goel A, Farrall M, Peloso GM, Won HH, Do R, van Iperen E, Kanoni S, Kruppa J, Mahajan A, Scott RA, Willenberg C, Braund PS, van Capelleveen JC, Doney AS, Donnelly LA, Asselta R, Merlini PA, Duga S, Marziliano N, Denny JC, Shaffer CM, El-Mokhtari NE, Franke A, Gottesman O, Heilmann S, Hengstenberg C, Hoffman P, Holmen OL, Hveem K, Jansson JH, Jöckel KH, Kessler T, Kriebel J, Laugwitz KL, Marouli E, Martinelli N, McCarthy MI, Van Zuydam NR, Meisinger C, Esko T, Mihailov E, Escher SA, Alver M, Moebus S, Morris AD, Müller-Nurasyid M, Nikpay M, Olivieri O, Lemieux Perreault LP, AlQarawi A, Robertson NR, Akinsanya KO, Reilly DF, Vogt TF, Yin W, Asselbergs FW, Kooperberg C, Jackson RD, Stahl E, Strauch K, Varga TV, Waldenberger M, Zeng L, Kraja AT, Liu C, Ehret GB, Newton-Cheh C, Chasman DI, Chowdhury R, Ferrario M, Ford I, Jukema JW, Kee F, Kuulasmaa K, Nordestgaard BG, Perola M, Saleheen D, Sattar N, Surendran P, Tregouet D, Young R, Howson JM, Butterworth AS, Danesh J, Ardissino… See abstract for full author list ➔ Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators, et al. N Engl J Med. 2016 Mar 24;374(12):1134-44. doi: 10.1056/NEJMoa1507652. Epub 2016 Mar 2. N Engl J Med. 2016. PMID: 26934567 Free PMC article.
  • A unified model for regulating lipoprotein lipase activity.
    Zhang R, Zhang K. Zhang R, et al. Trends Endocrinol Metab. 2024 Jun;35(6):490-504. doi: 10.1016/j.tem.2024.02.016. Epub 2024 Mar 23. Trends Endocrinol Metab. 2024. PMID: 38521668 Free PMC article. Review.
  • Regulation of lipoprotein lipase-mediated lipolysis of triglycerides.
    Basu D, Goldberg IJ. Basu D, et al. Curr Opin Lipidol. 2020 Jun;31(3):154-160. doi: 10.1097/MOL.0000000000000676. Curr Opin Lipidol. 2020. PMID: 32332431 Free PMC article. Review.

Cited by

References

    1. Wang H, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1775–1812. doi: 10.1016/S0140-6736(16)31470-2. - DOI - PMC - PubMed
    1. Nakanishi R, et al. Current but not past smoking increases the risk of cardiac events: insights from coronary computed tomographic angiography. Eur Heart J. 2015;36:1031–1040. doi: 10.1093/eurheartj/ehv013. - DOI - PMC - PubMed
    1. Lehrke M, Marx N. Diabetes mellitus and heart failure. Am J Med. 2017;130:S40–S50. doi: 10.1016/j.amjmed.2017.04.010. - DOI - PubMed
    1. Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet. 2017;18:331–344. doi: 10.1038/nrg.2016.160. - DOI - PMC - PubMed
    1. Kivimäki M, et al. Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data. Lancet. 2012;380:1491–1497. doi: 10.1016/S0140-6736(12)60994-5. - DOI - PMC - PubMed

Publication types

MeSH terms